HIV Vaccines: where are we, where are we

going, and how can we get there faster?

16 July 2010
Alan Bernstein, O.C., Ph.D.
Executive Director,
Global HIV Vaccine Enterprise
Estimated Number of Adults and Children
Newly Infected with HIV, 2008

Eastern Europe
Western & & Central Asia
Central Europe 110 000
North America 30 000 [100 000 – 130 000]
55 000 [23 000 – 35 000]
[36 000 – 61 000] East Asia
75 000
Caribbean [58 000 – 88 000]
20 000 Middle East & North Africa
[16 000 – 24 000] 35 000 South & South-East Asia
[24 000 – 46 000] 280 000
[240 000 – 320 000]
Latin America
170 000 Sub-Saharan Africa
[150 000 – 200 000] 1.9 million
[1.6 – 2.2 million] Oceania
3900
[2900 – 5100]

Total: 2.7 million (2.4 – 3.0 million)

Adapted from UNAIDS, December 2009

An Unsustainable Economic Situation
Prevention Approaches and Biomedical Interventions

Adapted from A. Fauci, NIH, 2009

Adapted from M. Robb, MHRP, 2010
How an HIV Vaccine
Might Work
Timeline Between Disease Identification and Vaccine Development

yellow rubella
fever measles hep. A
jap. encephalitis hepatitis B hepatitis C
mumps HIV
tetanus HPV
diphtheria influenza rotavirus
tuberculosis tick encephalitis
whooping cough chickenpox
polio cytomegalovirus
Streptococcal meningitis
Haemophilus influenza B
typhoid
malaria

1900 1920 1940 1960 1980 2000

How do we Develop Vaccines?

Efficacy trials

Phase 1 and II trials Clinical research

Product development and
animal testing
New vaccine
strategies
Fundamental
research
 Hope for an HIV Vaccine

RV144 Modified Intention-to-

Treat Analysis
 First proof of concept: a
vaccine is possible
 Need to understand how
vaccine reduced risk of HIV
acquisition
 Important implications for
future HIV vaccine design
and testing
Source: Rerks-Ngarm et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-I
Infection in Thailand. N Engl Med 2009; 361.
An Important Moment in HIV Vaccine Research
EMBARGOED UNTIL 11:15 a.m. CST Sunday, 18 July
The 2010 Plan: The Framework For A New Era of HIV Vaccine Research

• Developed by the Enterprise Council involving the

Enterprise Science Committee and five Working Groups
• Input of more than 400 researchers, policy-makers,
funders and advocates worldwide
• An agreement of partners to align their independent
strategies to maximize opportunities for cooperation in
HIV vaccine research
Transforming the Global HIV Vaccine Research Effort

Unified clinical trials Rapid data sharing New minds and new
agenda ideas

Broaden and increase funding

v
Global HIV Vaccine Enterprise:
Promoting Scientific Collaboration

AIDS Vaccine
Asian Network

v
Upcoming Enterprise 2010 Plan Activities
AIDS 2010, Vienna (18 – 23 July)
1.Satellite Session: The Search for an HIV Vaccine: Where are we, where are we
going, and how can we get there faster?”
11:15 – 13:15, Mini Room 6
2.Press Conference: Entering the Next Phase in HIV Vaccine Research, the Future
Course of the Field
Monday, 19 July 12:00 – 13:00, Press Room 1
3.Vaccine Session: HIV Vaccines – Quo Vadis?
Tuesday, 20 July 14:30 – 16:00, Session Room 3
4.Enterprise Booth
Section E, booth 476
 
AIDS Vaccine 2010, Atlanta (28 Sept. – 1 Oct.)
1.Plenary Session: Launch of the Global HIV Vaccine Enterprise 2010 Plan
Wednesday, 29 September 14:30 - 16:00